Abstract | AIM: METHODS: RESULTS: CONCLUSION: All-cause mortality was not different for any agent or regimen. In the absence of head-to-head comparisons, this network meta-analysis suggests that apixaban and dabigatran 110 mg bid may offer the best benefit-risk balance for stroke prevention in non-valvular atrial fibrillation. Dabigatran 150 mg bid may be preferred for patients with a high risk for embolism.
|
Authors | J Harenberg, S Marx, H-C Diener, G Y H Lip, V J Marder, M Wehling, C Weiss |
Journal | International angiology : a journal of the International Union of Angiology
(Int Angiol)
Vol. 31
Issue 4
Pg. 330-9
(Aug 2012)
ISSN: 1827-1839 [Electronic] Italy |
PMID | 22801398
(Publication Type: Journal Article, Meta-Analysis, Review)
|
Chemical References |
- Anticoagulants
- Benzimidazoles
- Morpholines
- Pyrazoles
- Pyridones
- Thiophenes
- beta-Alanine
- apixaban
- Rivaroxaban
- Dabigatran
|
Topics |
- Administration, Oral
- Aged
- Anticoagulants
(administration & dosage, adverse effects, therapeutic use)
- Atrial Fibrillation
(complications, drug therapy, mortality)
- Benzimidazoles
(administration & dosage, adverse effects, therapeutic use)
- Cerebral Hemorrhage
(chemically induced)
- Chi-Square Distribution
- Dabigatran
- Embolism
(etiology, mortality, prevention & control)
- Female
- Humans
- Male
- Middle Aged
- Morpholines
(administration & dosage, adverse effects, therapeutic use)
- Myocardial Infarction
(etiology)
- Odds Ratio
- Pyrazoles
(administration & dosage, adverse effects, therapeutic use)
- Pyridones
(administration & dosage, adverse effects, therapeutic use)
- Risk Assessment
- Risk Factors
- Rivaroxaban
- Stroke
(drug therapy, etiology, mortality)
- Thiophenes
(administration & dosage, adverse effects, therapeutic use)
- Treatment Outcome
- beta-Alanine
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
|